Article info

Original research
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

Authors

  • Niannian Ji Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADepartment of Urology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Neelam Mukherjee Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADepartment of Urology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Ryan M Reyes Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADivision of Hematology/Medical Oncology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Jonathan Gelfond Department of Epidemiology and Biostatistics, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Martin Javors Department of Psychiatry, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Joshua J. Meeks Departments of Urology, and Biochemistry and Molecular Genetics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • David J McConkey Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Zhen-Ju Shu Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADepartment of Urology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Chethan Ramamurthy Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADivision of Hematology/Medical Oncology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Ryan Dennett Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADepartment of Urology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Tyler J Curiel Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADivision of Hematology/Medical Oncology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  • Robert S Svatek Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USADepartment of Urology, UT Health San Antonio, San Antonio, Texas, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr. Robert S Svatek, Urology, UT Health San Antonio, San Antonio, Tx, USA; svatek{at}uthscsa.edu
View Full Text

Citation

Ji N, Mukherjee N, Reyes RM, et al
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

Publication history

  • Accepted January 26, 2021
  • First published March 2, 2021.
Online issue publication 
March 02, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.